Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers
Today, we’re launching The Psychedelic News Feed’s audio companion, available in your preferred podcast app.
Every other Monday, Psychedelic Alpha editor Josh Hardman will talk you through the preceding two weeks’ key developments across psychedelic drug development, policy, and access.
It’s certainly not a fully-fledged podcast. Rather, it’s a way to stay current and receive The Psychedelic News Feed in an audio format.
Listen to the first episode today. (Follow the podcast in your preferred app to receive new episodes directly.)
In this episode, Psychedelic Alpha’s editor Josh Hardman runs through a very busy two-week period in the field, including:
- Three meetings, or what I’m calling ‘Psychedelics Week’, in D.C.: FDA’s public hearing, an ibogaine-related meeting hosted by ARPA-H, and a congressional briefing
- A commentary published by top FDA staff outlining a model for psychedelic drug development
- New Zealand’s approval of two psychiatrists to prescribe MDMA
- And many other headlines, including: Definium Therapeutics’ Phase 3 LSD for generalised anxiety disorder readout, more data from Compass Pathways’ psilocybin for treatment-resistant depression program, Xylo’s neuroplastogen enters the clinic, Eli Lilly’s acquisition of AtaiBeckley closes, RFK Jr. hosts Bryan Hubbard on his podcast to talk ibogaine, and Usona Institute files a trademark on ‘Arumaya’ a potential brand name for its psilocybin candidate.
Subscribe to the Podcast Now
Listen to The Psychedelic News Feed Podcast on your preferred podcast app by clicking the link below.
Listen on your preferred appRead more about stories mentioned in this episode:
- No Questions Asked: FDA’s Psychedelics Public Hearing
- ‘Move Fast, with Precision’: Notes from ARPA-H’s Ibogaine Workshop
- Psychedelic Bulletin 231
- Field Notes #5: ‘Psychedelics Week’ in Washington D.C.
- Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD
- Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder
The Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks.
This episode of The Psychedelic News Feed is supported by
As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety.
Learn more